1.Experience in Treating Depression with the Combined Use of Acupuncture and Herbal Medicine Under the Guiding Principle of Deficiency and Excess
Yuxian WANG ; Wei LU ; Hengjia LIU ; Jing YANG ; Qingnan FU ; Jie ZHANG
Journal of Traditional Chinese Medicine 2025;66(14):1499-1503
This paper summarizes clinical experience in treating depression with a combined approach of acupuncture and herbal medicine under the guiding principle of deficiency and excess. Given the complex pathogenesis of depression, it is proposed that syndrome differentiation based on deficiency and excess should serve as the overarching principle. Acupuncture is prioritized, supplemented by Chinese herbal medicine. Acupuncture is based on the spirit-regulating protocol; for excess syndromes, it is combined with the calming and restoring protocol, while for deficiency syndromes, it is combined with the five zang organs tonification protocol. In cases of mixed deficiency and excess, the two protocols are alternated, and adjustments are made dynamically throughout the treatment based on syndrome evolution. Herbal prescriptions are also guided by the differentiation of deficiency and excess. For excess patterns, dispersion and clearance should be emphasized, focusing on soothing the liver, clearing heat, relieving irritability, regulating qi, transforming phlegm, and calming the mind; for deficiency patterns, tonification is emphasized, aiming to strengthen the spleen, nourish the blood, calm the spirit, tonify qi, and consolidate the root.
2.Analysis of the changes of upper airway and adenoids in children with skeletal class Ⅰ and class Ⅲanterior crossbite after orthodontic treatment
Lu YU ; Yuxian XIN ; Feiyan YU ; Xuejun GE
Journal of Practical Stomatology 2025;41(6):788-792
Objective:To investigate the changes of upper airway and adenoids in children with hypertrophic adenoid skeletal classⅠ and class Ⅲ anterior crossbite after orthodontic treatment.Methods:From January 2021 to January 2022,155 children with skeletal class Ⅲ anterior crossbite who were treated with anterior traction in Stomatological Hospital,Shanxi Medical University were selected.They were divided into class Ⅲ normal group(72 cases)and class Ⅲ hypertrophic group(83 cases)according to whether the adenoids were hypertrophic.A total of 122 children with class Ⅰ anterior counterocclusion were treated with"2×4"treatment,which were di-vided into Class Ⅰ normal group(60 cases)and class Ⅰ hypertrophy group(62 cases).The changes of upper airway and adenoid were compared between the two groups.Results:(1)After intervention,only the width of nasopharynx cavity increased(P<0.05)in Class Ⅰ normal group and Class Ⅰ hypertrophic group,and there was no significant difference in other indicators(P>0.05).(2)After intervention,the adenoid thickness and A/N ratio of children with skeletal class Ⅲ anterior crossbite decreased,and the width of na-sopharynx cavity,nasopharynx airway space,soft palate upper and rear airway space,uvula tip rear airway space,the minimum air-way space between soft palate and adenoid,and mandibular plane angle increased(P<0.05).The A/N ratio of class Ⅲ hypertrophic group was lower than that of class Ⅲ normal group(P<0.05).Conclusion:Orthodontic treatment can reduce the degree of adenoid hypertrophy and expand the airway in children with skeletal class Ⅲ anterior crossbite.Only the width of the nasopharynx cavity can be widened after the correction intervention for children with adenoid hypertrophy and skeletal class Ⅰ anterior crossbite.
3.Risk Assessment of Radiation Prevention and Treatment Drugs
Ran ZHANG ; Chang LU ; Huan LONG ; Keer XUAN ; Wanlong ZHANG ; Yuxian ZHANG ; Hongzhu LIU ; Dong CHAI ; Jian GONG
Herald of Medicine 2025;44(10):1648-1654
Radiation prevention and treatment drugs are a rapidly developing field.Radiation prevention and treatment drugs can be roughly divided into four categories:chemical synthetic drugs,biological products,natural plant extracts and traditional Chinese medicine compounds,which are widely used in medical,scientific research and other fields.This paper reviews the classification of radiation prevention and treatment drugs,which can be roughly divided into four categories:chemical synthetic drugs,biological products,natural plant extracts and traditional Chinese medicine compounds.At the same time,its mechanism of action and clinical application are elaborated in detail,and the risk assessment is carried out from the aspects of effectiveness,safety and drug interaction.Finally,the risk reduction strategies are summarized from the aspects of clinical medication specification and monitoring,continuous drug safety research,improvement of emergency reserve and support capacity and construction of full-cycle regulatory system,so as to provide reference for the rational application and further research of radiation prevention and treatment drugs.
4.Analysis of the changes of upper airway and adenoids in children with skeletal class Ⅰ and class Ⅲanterior crossbite after orthodontic treatment
Lu YU ; Yuxian XIN ; Feiyan YU ; Xuejun GE
Journal of Practical Stomatology 2025;41(6):788-792
Objective:To investigate the changes of upper airway and adenoids in children with hypertrophic adenoid skeletal classⅠ and class Ⅲ anterior crossbite after orthodontic treatment.Methods:From January 2021 to January 2022,155 children with skeletal class Ⅲ anterior crossbite who were treated with anterior traction in Stomatological Hospital,Shanxi Medical University were selected.They were divided into class Ⅲ normal group(72 cases)and class Ⅲ hypertrophic group(83 cases)according to whether the adenoids were hypertrophic.A total of 122 children with class Ⅰ anterior counterocclusion were treated with"2×4"treatment,which were di-vided into Class Ⅰ normal group(60 cases)and class Ⅰ hypertrophy group(62 cases).The changes of upper airway and adenoid were compared between the two groups.Results:(1)After intervention,only the width of nasopharynx cavity increased(P<0.05)in Class Ⅰ normal group and Class Ⅰ hypertrophic group,and there was no significant difference in other indicators(P>0.05).(2)After intervention,the adenoid thickness and A/N ratio of children with skeletal class Ⅲ anterior crossbite decreased,and the width of na-sopharynx cavity,nasopharynx airway space,soft palate upper and rear airway space,uvula tip rear airway space,the minimum air-way space between soft palate and adenoid,and mandibular plane angle increased(P<0.05).The A/N ratio of class Ⅲ hypertrophic group was lower than that of class Ⅲ normal group(P<0.05).Conclusion:Orthodontic treatment can reduce the degree of adenoid hypertrophy and expand the airway in children with skeletal class Ⅲ anterior crossbite.Only the width of the nasopharynx cavity can be widened after the correction intervention for children with adenoid hypertrophy and skeletal class Ⅰ anterior crossbite.
5.Risk Assessment of Radiation Prevention and Treatment Drugs
Ran ZHANG ; Chang LU ; Huan LONG ; Keer XUAN ; Wanlong ZHANG ; Yuxian ZHANG ; Hongzhu LIU ; Dong CHAI ; Jian GONG
Herald of Medicine 2025;44(10):1648-1654
Radiation prevention and treatment drugs are a rapidly developing field.Radiation prevention and treatment drugs can be roughly divided into four categories:chemical synthetic drugs,biological products,natural plant extracts and traditional Chinese medicine compounds,which are widely used in medical,scientific research and other fields.This paper reviews the classification of radiation prevention and treatment drugs,which can be roughly divided into four categories:chemical synthetic drugs,biological products,natural plant extracts and traditional Chinese medicine compounds.At the same time,its mechanism of action and clinical application are elaborated in detail,and the risk assessment is carried out from the aspects of effectiveness,safety and drug interaction.Finally,the risk reduction strategies are summarized from the aspects of clinical medication specification and monitoring,continuous drug safety research,improvement of emergency reserve and support capacity and construction of full-cycle regulatory system,so as to provide reference for the rational application and further research of radiation prevention and treatment drugs.
6.Accuracy evaluation of bioelectrical impedance analysis in assessment of appendicular skeletal muscle mass in adults aged 18-42 years
Yiying ZHENG ; Hong CHENG ; Yuxian KUANG ; Zhenxin MA ; Weiye CHEN ; Keyuan LU ; Jie MI ; Li LIU
The Journal of Practical Medicine 2024;40(4):549-553
Objective To evaluate the accuracy of bioelectrical impedance analysis(BIA)in measurement of appendicular skeletal muscle mass(ASM)of adults.Methods A total of 836 adults aged 18-42 years were recruited in Guangzhou using a convenient sampling method from April 2021 to September 2022.ASM was measured using BIA and Dual-energy X-ray absorptiometry(DXA).Using DXA as the standard method,the consistency between the BIA and DXA measurements was evaluated by intra-class correlation coefficients(ICCs)and Bland-Altman analysis in logarithmically transformed data,in order to evaluate the accuracy of BIA in ASM measurement.Receiver operating characteristic curve was plotted to evaluate the diagnostic value of BIA for screening low muscle mass.Results A total of 774 individuals were included for analysis finally.ICCs for ASM measured by BIA and DXA were 0.774 and 0.667 in males and females,respectively.Mean ratios(limits of Agreement)of ASM were 0.94(0.80-1.10)and 0.91(0.78-1.05)in males and females,respectively.Area under curve of BIA for screening low muscle mass were 0.91 and 0.94 in males and females,respectively.The optimal cut-off values of Z-score by BIA for males and females were-0.57 and-0.66,respectively.Sensitivity and specificity for males were 82.5%and 86.0%,while being 86.8%and 93.8%,for females.Conclusion BIA shows a moderate consistency with DXA for measuring ASM in adults.Furthermore,BIA yields a good diagnostic value in identifying low muscle mass in adults aged 18-42 years.
7.Pharmacovigilance for Radiopharmaceuticals
Yue SUN ; Yuxuan ZHENG ; Zhenjiang ZHANG ; Yuxian ZHANG ; Ran ZHANG ; Chang LU ; Li ZHANG ; Ding LI ; Jiachen TU ; Jing XIE ; Huan ZHOU ; Jian GONG
Herald of Medicine 2024;43(10):1615-1619
Radiopharmaceuticals play an important role in the medical field,but they also carry certion risks and potential safety concerns.Medical institutions implement pharmacovigilance to ensure the safety of patients'drug use,including the safety of Radiopharmaceuticals.The operation and management of the pharmacovigilance system in the United States and the European Union are relatively mature.China can learn from their advanced concepts and establish our own radiopharmaciligence system.
8.α2-macroglobulin alleviates glucocorticoid-induced avascular necrosis of the femoral head in mice by promoting proliferation, migration and angiogenesis of vascular endothelial cells
Qi ZHU ; Yunxiang LU ; You PENG ; Jiale HE ; Zeyu WEI ; Zhiyong LI ; Yuxian CHEN
Journal of Southern Medical University 2024;44(4):712-719
Objective To explore the mechanism underlying the protective effect of α2-macroglobulin (A2M) against glucocorticoid-induced femoral head necrosis. Methods In a human umbilical vein endothelial cell (HUVEC) model with injuries induced by gradient concentrations of dexamethasone (DEX;10-8-10-5 mol/L), the protective effects of A2M at 0.05 and 0.1 mg/mL were assessed by examining the changes in cell viability, migration, and capacity of angiogenesis using CCK-8 assay, Transwell and scratch healing assays and angiogenesis assay. The expressions of CD31 and VEGF-A proteins in the treated cells were detected using Western blotting. In BALB/c mouse models of avascular necrosis of the femoral head induced by intramuscular injections of methylprednisolone, the effects of intervention with A2M on femoral trabecular structure, histopathological characteristics, and CD31 expression were examined with Micro-CT, HE staining and immunohistochemical staining. Results In cultured HUVECs, DEX treatment significantly reduced cell viability, migration and angiogenic ability in a concentration- and time-dependent manner (P<0.05), and these changes were obviously reversed by treatment with A2M in positive correlation with A2M concentration (P<0.05). DEX significantly reduced the expression of CD31 and VEGF-A proteins in HUVECs, while treatment with A2M restored CD31 and VEGF-A expressions in the cells (P<0.05). The mouse models of femoral head necrosis showed obvious trabecular damages in the femoral head, where a large number of empty lacunae and hypertrophic fat cells could be seen and CD31 expression was significantly decreased (P<0.05). A2M treatment of the mouse models significantly improved trabecular damages, maintained normal bone tissue structures, and increased CD31 expression in the femoral head (P<0.05). Conclusion A2M promotes proliferation, migration, and angiogenesis of DEX-treated HUVECs and alleviates methylprednisolone-induced femoral head necrosis by improving microcirculation damages and maintaining microcirculation stability in the femoral head.
9.α2-macroglobulin alleviates glucocorticoid-induced avascular necrosis of the femoral head in mice by promoting proliferation, migration and angiogenesis of vascular endothelial cells
Qi ZHU ; Yunxiang LU ; You PENG ; Jiale HE ; Zeyu WEI ; Zhiyong LI ; Yuxian CHEN
Journal of Southern Medical University 2024;44(4):712-719
Objective To explore the mechanism underlying the protective effect of α2-macroglobulin (A2M) against glucocorticoid-induced femoral head necrosis. Methods In a human umbilical vein endothelial cell (HUVEC) model with injuries induced by gradient concentrations of dexamethasone (DEX;10-8-10-5 mol/L), the protective effects of A2M at 0.05 and 0.1 mg/mL were assessed by examining the changes in cell viability, migration, and capacity of angiogenesis using CCK-8 assay, Transwell and scratch healing assays and angiogenesis assay. The expressions of CD31 and VEGF-A proteins in the treated cells were detected using Western blotting. In BALB/c mouse models of avascular necrosis of the femoral head induced by intramuscular injections of methylprednisolone, the effects of intervention with A2M on femoral trabecular structure, histopathological characteristics, and CD31 expression were examined with Micro-CT, HE staining and immunohistochemical staining. Results In cultured HUVECs, DEX treatment significantly reduced cell viability, migration and angiogenic ability in a concentration- and time-dependent manner (P<0.05), and these changes were obviously reversed by treatment with A2M in positive correlation with A2M concentration (P<0.05). DEX significantly reduced the expression of CD31 and VEGF-A proteins in HUVECs, while treatment with A2M restored CD31 and VEGF-A expressions in the cells (P<0.05). The mouse models of femoral head necrosis showed obvious trabecular damages in the femoral head, where a large number of empty lacunae and hypertrophic fat cells could be seen and CD31 expression was significantly decreased (P<0.05). A2M treatment of the mouse models significantly improved trabecular damages, maintained normal bone tissue structures, and increased CD31 expression in the femoral head (P<0.05). Conclusion A2M promotes proliferation, migration, and angiogenesis of DEX-treated HUVECs and alleviates methylprednisolone-induced femoral head necrosis by improving microcirculation damages and maintaining microcirculation stability in the femoral head.
10.Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)
Xi WANG ; Ying LIU ; Junxing HUANG ; Ping LU ; Yi BA ; Lin WU ; Yuxian BAI ; Shu ZHANG ; Jifeng FENG ; Ying CHENG ; Jie LI ; Lu WEN ; Xianglin YUAN ; Changwu MA ; Chunhong HU ; Qingxia FAN ; Binghe XU ; Jing HUANG
Chinese Journal of Oncology 2021;43(11):1177-1182
Objective:To investigate the correlation between UGT1A1 polymorphisms and the irinotecan plus S-1 regimen-induced toxicities in Chinese advanced esophageal squamous cell carcinoma (ESCC) patients.Methods:A total of 46 recurrent or metastatic ESCC patients selected from ESWN 01 trial were randomly assigned to irinotecan plus S-1 group [intravenous infusion of irinotecan (160 mg/m 2) on day 1 and oral S-1 (80-120 mg) on days 1-10, repeated every 14 days]. Peripheral venous blood at baseline was collected and genomic DNA was extracted. The genetic polymorphisms of UGT1A1*6 and UGT1A1*28 were analyzed by polymerase chain reaction (PCR) amplification. Irinotecan plus S-1 regimen-induced toxicities of patients with different UGT1A1 polymorphisms were observed. The correlation between UGT1A1 polymorphisms and the adverse effects was analyzed. Results:Among the 46 patients, the numbers of UGT1A1*6 wild type genotype (GG), mutant heterozygote (GA) and mutant homozygote (AA) were 30, 15 and 1, while those with UGT1A1*28 wild type genotype (TA6/6), mutant heterozygote (TA6/7) and mutant homozygote (TA7/7) were 36, 8 and 2, respectively. Only one patient with UGT1A1*6 AA genotype occurred grade 3 diarrhea, while one of the 2 patients with UGT1A1*28 TA7/7 genotype occurred grade 4 diarrhea. No neutropenia was observed in the patient with UGT1A1*6 AA genotype, however, both of the two patients with UGT1A1*28 TA7/7 genotype occurred grade 3-4 neutropenia. Patients with UGT1A1*28 genetic polymorphism (TA 6/7 or TA7/7) had a higher response rate compared with wild-type TA6/6 carriers. (55.6% versus 26.5%).Conclusions:The homozygous genotype of UGT1A1*6 AA and UGT1A1*28 TA7/7 are rare (<5%) in Chinese ESCC population. Not all homozygous AA and TA7/7 carriers occur severe dose limited toxicities (DLT) when treated with irinotecan (160 mg/m 2) plus S-1 regimen for 2 weeks. However, it′s still necessary torigorously observe the occurrence of severe diarrhea and neutropenia in patients with UGT1A1*6 AA and UGT1A1*28 TA7/7 and adjust the dose timely.

Result Analysis
Print
Save
E-mail